Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Salagen approved for Sjogren's syndrome in Canada

Aug. 20, 1997

New treatment for osteoarthritis approved for marketing in U.S.

Aug. 18, 1997

Antiinflammatory drugs in early development at Searle

Aug. 13, 1997

MMP/TNF-alpha inhibitors from Novartis

Aug. 12, 1997

Amarillo Biosciences completes enrollment for phase II study on Sjogren's syndrome

Aug. 12, 1997

Cephalon reports cysteine/serine protease inhibitors with broad therapeutic potential

Aug. 11, 1997

Antiarthritic activity of British Biotech MMP/TNF-alpha inhibitors

Aug. 8, 1997

Nabumetone shows superior safety profile in comparative study

Aug. 6, 1997

Neoral as rheumatoid arthritis therapy launched in U.S.

Aug. 1, 1997

Cell adhesion inhibitors disclosed by Hoechst

July 31, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.